New diabetes shot SHR-3167 enters early human testing

NCT ID NCT07032688

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial tests a new injectable drug called SHR-3167 in 55 adults with type 2 diabetes. The study measures how the drug moves through the body and how well it controls blood sugar. Participants will receive either SHR-3167 or insulin degludec to compare their effects and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR-3167 injection

What this could lead to

If successful, this could lead to a new once-daily insulin-like option for managing type 2 diabetes.

What could go wrong

This is an early Phase 1 study with only 55 people, so safety and effectiveness are not yet proven. The drug may cause hypoglycemia or other side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 200433, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact